How to get AOD-9604: the honest route, and why to pause

Last updated 2026-07-24

What is AOD-9604 and where did it come from?

AOD-9604 is a synthetic fragment of human growth hormone, specifically the region of the HGH molecule (amino acids 176-191) that researchers linked to fat metabolism without the growth-promoting effects of full-length HGH. The idea was to isolate the "good part" for fat loss and drop the parts that raise insulin resistance or bone/organ growth risk. It was developed and studied through the mid-2000s as an obesity drug candidate, covered in a 2004 review of AOD-9604's metabolic profile in Current Opinion in Investigational Drugs ^[1], and again in a 2006 survey of obesity drugs in clinical development that placed it among a crowded field of anti-obesity candidates at the time ^[2]. It never became an approved medicine. That single fact should frame everything else in this article. More recent literature treats AOD-9604 less as an obesity drug and more as a peptide of interest in orthopaedic and musculoskeletal contexts, per a 2026 review of therapeutic peptides in orthopaedics ^[3] and a 2026 sports medicine review of peptide therapies for musculoskeletal injuries and athletic performance ^[4]. Neither of those reviews is about fat loss claims, and neither substitutes for the original obesity trial record.

Did AOD-9604 actually work for fat loss in human trials?

This is the part sellers don't want you dwelling on. AOD-9604 went through human obesity trials, and the weight-loss signal did not separate convincingly from placebo. The 2004 metabolic review ^[1] and the 2006 obesity-pipeline review ^[2] both cover this era of development, and AOD-9604 did not advance to approval as an obesity treatment, which is itself the strongest evidence about how the trial data actually read out. Compare that to what happened with the GLP-1 class over the same two decades: semaglutide and tirzepatide went through Phase 3 programs that produced double-digit percentage body weight loss in randomized trials, and both are now FDA-approved drugs listed in the Drugs@FDA database ^[5]. AOD-9604 never got there. If you're choosing between "a fragment peptide with an unconvincing 2000s trial record" and "an approved drug with a large, replicated Phase 3 program," that's not actually a close call on the evidence. None of this means the fat-metabolism mechanism was nonsense on paper. It means the mechanism didn't translate into a body-composition result that beat placebo by a margin worth marketing. That distinction matters if you're about to spend money on it.

How do people actually get AOD-9604 right now?

There are really only two lanes, and neither is a retail pharmacy handing you an FDA-approved box. Lane one is research-chemical sellers, who sell AOD-9604 as "not for human consumption" vials aimed at lab use. This is the lane most people mean when they ask how to get it, and it's also the lane with zero quality assurance layer between the vial and your body. No FDA review, no batch consistency guarantee, no chain of custody. Lane two is compounding pharmacies, which operate under a different legal framework entirely. Compounders working under section 503A of the Food, Drug and Cosmetic Act (21 U.S.C. 353a) can prepare a drug for an individual patient under a prescription, but only using bulk substances that appear on FDA's approved lists for compounding, found at 21 CFR 216.23 for 503A pharmacies ^[6] and 21 CFR 216.24 for 503B outsourcing facilities ^[7]. FDA maintains the current nominated bulk substances list ^[8], and you can check it directly rather than trusting a seller's claim that a peptide is "compoundable." The practical difference: a 503A/503B pharmacy route at least puts a licensed provider and a regulated facility between you and the syringe. A research-chemical vial puts nothing between you and the syringe except a website's word.

Is AOD-9604 legal to buy and use?

It depends entirely on what you're buying it for and from whom, and this is genuinely gray in a way sellers gloss over. FDA's rule on "intended use" (21 CFR 201.128) ^[9] says a product's legal status turns on what it's marketed and used for, more than its chemical identity. A vial labeled "research use only" that's actually being sold and used for human fat loss is being marketed contrary to its stated intended use, which is exactly the gray zone that gets research-chemical sellers into regulatory trouble. AOD-9604 has no FDA drug approval for any human indication, so there is no legal retail lane for it as a weight-loss product, full stop. You can verify any peptide's approval status yourself in the Drugs@FDA database ^[5]; AOD-9604 doesn't appear there as an approved product. The compounding lane is narrower and more defensible legally, but it still requires that the specific substance sit on the 503A or 503B bulks list ^[6][7], and it still requires a prescriber willing to write for an unapproved indication, which most legitimate providers are cautious about given the weak trial record.

What does provider-reviewed sourcing actually mean?

"Provider-reviewed" means a licensed prescriber looks at your history, decides whether there's a legitimate rationale, and if so, sends the order to a compounding pharmacy operating under the 503A framework rather than you buying loose vials off a research-chemical site. This doesn't fix the evidence problem. A provider signing off on AOD-9604 doesn't make the 2004-2006 trial data ^[1][2] any stronger. What it does fix is the supply chain: you get a facility that's subject to state board of pharmacy oversight and FDA's compounding rules, instead of an anonymous overseas vial supplier. AOD-9604 Co's position is that if you're going to source this peptide at all, the provider-reviewed and pharmacy-fulfilled route is the only one worth considering, because it at least removes the identity and purity uncertainty that dominates research-chemical sourcing. It does not remove the efficacy uncertainty, which is a separate and larger problem you should sit with before you order anything.

What should I check before buying from any AOD-9604 source?

Ask for a Certificate of Analysis (CoA) from a third-party lab, not the seller's in-house paperwork, and check that the lot number on the CoA matches the vial you'd actually receive. A lot of research-chemical listings show a CoA for a different batch entirely. Check whether the seller claims any FDA relationship or approval status; any claim that AOD-9604 is "FDA-approved" or "FDA-registered" is false on its face; you can confirm this yourself in the Drugs@FDA database ^[5], which lists every approved drug product and application. If you're going the compounding route, ask your provider or pharmacy directly whether AOD-9604 is on FDA's current bulk substances list for 503A compounding ^[8], and don't take a verbal "yes" as sufficient. Ask them to point you to the entry. And separate from all of that: ask yourself honestly whether the trial evidence ^[1][2] justifies the cost, given that an approved alternative with a much stronger Phase 3 record exists for the same goal.

Will AOD-9604 show up on a drug test or WADA screen?

This matters if you're an athlete under testing, and the answer is nuanced. A 2013 study in Drug Testing and Analysis found that AOD-9604 does not influence the WADA hGH isoform immunoassay, meaning it wouldn't trigger a positive on that specific test the way full-length HGH would ^[10]. That is not the same as saying AOD-9604 is undetectable or permitted. Separate detection methods exist specifically for peptide fragments like this. A 2014 review in Expert Review of Proteomics on detecting peptidic drugs and analogs in sports doping ^[11], and a 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis on analytical approaches for emerging therapeutics in doping controls ^[12], both describe methods built to catch exactly this class of compound. A 2016 method in the Journal of Separation Science demonstrated direct urine injection screening for peptides under 2 kDa, a size range that includes AOD-9604 ^[13]. In plain terms: it won't necessarily flag the standard HGH test, but dedicated peptide-screening methods built in the years since are designed to find it anyway. If you're tested under WADA rules, assume detectable, not assume safe.

How much does AOD-9604 cost and is it worth the price?

Pricing varies widely across research-chemical sellers and compounding pharmacies, and neither type of seller publishes a standardized price the way an FDA-approved drug's list price gets tracked. Expect meaningful price swings between sources selling the same nominal dose, which itself is a red flag for a market with no enforced pricing or purity standard. The more useful question isn't "what does it cost" but "what am I paying for." You're paying for a peptide whose obesity trial data, per the 2004 ^[1] and 2006 ^[2] reviews, didn't produce a placebo-beating weight-loss result convincing enough to earn approval. Compare that to what an approved GLP-1 drug costs and delivers, verifiable through the FDA-approved product listing ^[5], and the AOD-9604 spend starts looking like it's buying uncertainty rather than results. If you still want to proceed, at minimum insist on the provider-reviewed, pharmacy-fulfilled path rather than a straight-to-consumer vial. You're not getting better efficacy that way. You're getting better sourcing integrity, which is the only lever actually available to you here.

What are the real alternatives with stronger evidence?

If your actual goal is fat loss, and you're comparing options on trial strength rather than novelty, the approved GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 randomized trial programs behind their FDA approvals, listed in the Drugs@FDA database ^[5], with published body weight reductions in the double-digit percentage range across their main trials. AOD-9604 has no equivalent program and no approval. If your interest in AOD-9604 is actually about musculoskeletal or connective tissue application rather than fat loss, that's a different conversation with different literature; the 2026 orthopaedic peptide review ^[3] and the 2026 sports medicine peptide review ^[4] cover that territory, and neither claims fat-loss efficacy as their finding. Don't let a fragment peptide with a 20-year-old inconclusive obesity trial record borrow credibility from a completely different application area. Read the aod 9604 peptide overview for the full mechanism and trial history side by side, and check aod 9604 peptide side effects before you consider dosing at all.

If I still want to try it, what's the responsible next step?

Read the trial evidence first, not the seller copy. Start with the original metabolic review ^[1] and the obesity pipeline context ^[2], and be honest with yourself about what "did not separate convincingly from placebo" means for your expectations. If you decide to proceed anyway, go through a provider-reviewed route rather than an anonymous research-chemical vial. That means a licensed prescriber evaluates you, and a compounding pharmacy operating under the 503A framework ^[6] fulfills the order, rather than a drop-shipped vial with a self-issued CoA. From there, understand dosing and reconstitution before anything touches a syringe; see aod 9604 dosage, aod 9604 how to reconstitute, and use the aod 9604 dosage calculator rather than eyeballing a protocol from a forum post. If you're comparing where to actually source it once you've made an informed decision, aod 9604 peptide for sale walks through what a provider-reviewed, pharmacy-fulfilled order looks like end to end.

Frequently asked questions

Can I buy AOD-9604 legally in the US?

There's no FDA-approved retail product, so "legal" depends on the channel. A compounding pharmacy can prepare it for an individual patient under a prescription only if the substance is on FDA's 503A bulks list (21 CFR 216.23) ^[6]. Research-chemical vials sold for human use, despite "not for human consumption" labeling, sit in a legally gray and unregulated space.

Does AOD-9604 actually cause fat loss in humans?

The human obesity trial data from the mid-2000s did not show weight loss that convincingly beat placebo, which is reflected in the fact that AOD-9604 never earned FDA approval as an obesity treatment ^[1][2]. Treat any current fat-loss claim as unsupported by the existing published trial record.

What's the difference between research-chemical AOD-9604 and pharmacy-compounded AOD-9604?

Research-chemical vials come with no prescriber oversight, no guaranteed regulatory framework, and inconsistent purity documentation. Compounded versions, when the substance qualifies under 21 CFR 216.23 ^[6], involve a licensed prescriber and a pharmacy under FDA and state board oversight, though neither route changes the underlying weak trial evidence.

Will AOD-9604 show up on a doping test?

It doesn't trigger the WADA hGH isoform immunoassay specifically ^[10], but dedicated peptide-detection methods built for compounds under 2 kDa, described in 2014 and 2016 analytical chemistry papers ^[11][12][13], are designed to catch it. Assume it's detectable under modern testing panels.

Is AOD-9604 FDA-approved?

No. It has never appeared as an approved product in the Drugs@FDA database ^[5], and it did not advance past investigational obesity trials in the mid-2000s ^[1][2]. Any seller claiming FDA approval or FDA registration for AOD-9604 is making a false claim.

How much does AOD-9604 typically cost?

Pricing varies widely across research-chemical sellers and compounding pharmacies, with no standardized list price the way an approved drug has. The wide spread itself is a signal of an unregulated market; always request a third-party Certificate of Analysis matching the specific lot before paying.

What should I ask a compounding pharmacy before ordering AOD-9604?

Ask whether the substance appears on FDA's current nominated bulk substances list for 503A compounding ^[8], and ask to see that confirmation directly rather than accepting a verbal yes. Also confirm the pharmacy is licensed in your state and operating under section 503A (21 U.S.C. 353a) ^[14].

Are there stronger alternatives to AOD-9604 for weight loss?

Yes. FDA-approved GLP-1 receptor agonists have large Phase 3 randomized trial programs behind their approvals, verifiable in the Drugs@FDA database ^[5], with body weight reductions well beyond what any published AOD-9604 obesity trial demonstrated. If fat loss is the actual goal, that evidence gap is worth weighing seriously.

Why did AOD-9604 fail to reach approval as an obesity drug?

The published record indicates the weight-loss effect did not separate convincingly from placebo in human trials, covered in a 2004 metabolic review ^[1] and a 2006 obesity drug pipeline review ^[2]. Neither source claims a clear efficacy signal strong enough to support approval.

Is AOD-9604 used for anything other than fat loss now?

Recent literature discusses AOD-9604 in orthopaedic and musculoskeletal contexts rather than obesity, per 2026 reviews in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews ^[3] and Sports Medicine ^[4]. These don't establish fat-loss efficacy; they're a separate research thread.

What is the AOD-9604 fragment supposed to do mechanistically?

It's built from amino acids 176-191 of human growth hormone, the region researchers associated with fat metabolism, with the intent of separating that effect from HGH's growth-promoting and insulin-resistance effects ^[1]. The mechanism was plausible on paper; the human trial results didn't confirm a strong clinical benefit.

Do I need a prescription to get AOD-9604 through a pharmacy?

Yes, for the compounding route. Under section 503A (21 U.S.C. 353a) ^[14], a pharmacy can only prepare a compounded drug for an individual patient with a valid prescription from a licensed prescriber, and only using substances on FDA's approved bulks list ^[6].

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): 2004 review of AOD-9604's metabolic profile and mechanism as a fat-metabolism HGH fragment
2. PubMed, Current Opinion in Investigational Drugs (2006): 2006 review placing AOD-9604 among obesity drugs in clinical development, none of which reached approval as AOD-9604
3. PubMed, JAAOS Global Research & Reviews (2026): 2026 review discussing AOD-9604 in orthopaedic/musculoskeletal peptide therapy context, not fat loss
4. PubMed, Sports Medicine (2026): 2026 review of safety and efficacy of approved/unapproved peptide therapies for musculoskeletal injury and athletic performance
5. FDA, Drugs@FDA database: AOD-9604 has no FDA-approved drug listing; GLP-1 drugs like semaglutide and tirzepatide are listed as approved
6. eCFR, 21 CFR 216.23 (503A Bulks List): 503A compounding pharmacies may only use bulk substances on FDA's approved bulks list
7. eCFR, 21 CFR 216.24 (503B Bulks List): 503B outsourcing facilities operate under a separate bulk substances list from 503A pharmacies
8. FDA, Bulk drug substances nominated for compounding (current list): FDA maintains a current list of bulk substances nominated for compounding use that can be checked directly
9. eCFR, 21 CFR 201.128 (Meaning of intended uses): A product's legal status under FDA rules turns on its intended use, more than its labeling as research-only
10. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay
11. PubMed, Expert Review of Proteomics (2014): Analytical methods exist specifically to detect peptidic drugs and analogs like AOD-9604 in doping controls
12. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Analytical approaches developed for detecting emerging therapeutics and non-approved drugs in doping controls
13. PubMed, Journal of Separation Science (2016): Direct urine injection LC-ion mobility mass spectrometry method screens for peptides under 2 kDa, a range including AOD-9604
14. Cornell Law School, 21 U.S.C. 353a (Pharmacy compounding): Section 503A requires a valid prescription from a licensed prescriber for individual patient compounding